TY - JOUR
T1 - Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) – Diabetes
T2 - rationale and design
AU - Nelson, Adam J.
AU - Pagidipati, Neha J.
AU - Kelsey, Michelle D.
AU - Ardissino, Maddalena
AU - Aroda, Vanita R.
AU - Cavender, Matthew A.
AU - Lopes, Renato D.
AU - Al-Khalidi, Hussein R.
AU - Braceras, Rogelio
AU - Gaynor, Tanya
AU - Kaltenbach, Lisa A.
AU - Kirk, Julienne K.
AU - Lingvay, Ildiko
AU - Magwire, Melissa L.
AU - O'Brien, Emily C.
AU - Pak, Jonathan
AU - Pop-Busui, Rodica
AU - Richardson, Caroline R.
AU - Levya, Monica
AU - Senyucel, Cagri
AU - Webb, Laura
AU - McGuire, Darren K.
AU - Green, Jennifer B.
AU - Granger, Christopher B.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/2
Y1 - 2023/2
N2 - Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice. Clinician, patient, and system-level barriers all contribute to these gaps in care; yet, there is a paucity of high quality, rigorous studies evaluating the role of interventions to increase utilization. The COORDINATE-Diabetes trial randomized 42 cardiology clinics across the United States to either a multifaceted, site-specific intervention focused on evidence-based care for patients with T2DM or standard of care. The multifaceted intervention comprised the development of an interdisciplinary care pathway for each clinic, audit-and-feedback tools and educational outreach, in addition to patient-facing tools. The primary outcome is the proportion of individuals with T2DM prescribed three key classes of evidence-based medications (high-intensity statin, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and either a sodium/glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor or glucagon-like peptide 1 receptor agonist (GLP-1RA) and will be assessed at least 6 months after participant enrollment. COORDINATE-Diabetes aims to identify strategies that improve the implementation and adoption of evidence-based therapies.
AB - Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice. Clinician, patient, and system-level barriers all contribute to these gaps in care; yet, there is a paucity of high quality, rigorous studies evaluating the role of interventions to increase utilization. The COORDINATE-Diabetes trial randomized 42 cardiology clinics across the United States to either a multifaceted, site-specific intervention focused on evidence-based care for patients with T2DM or standard of care. The multifaceted intervention comprised the development of an interdisciplinary care pathway for each clinic, audit-and-feedback tools and educational outreach, in addition to patient-facing tools. The primary outcome is the proportion of individuals with T2DM prescribed three key classes of evidence-based medications (high-intensity statin, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and either a sodium/glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor or glucagon-like peptide 1 receptor agonist (GLP-1RA) and will be assessed at least 6 months after participant enrollment. COORDINATE-Diabetes aims to identify strategies that improve the implementation and adoption of evidence-based therapies.
UR - http://www.scopus.com/inward/record.url?scp=85142541430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142541430&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2022.10.079
DO - 10.1016/j.ahj.2022.10.079
M3 - Article
C2 - 36279931
AN - SCOPUS:85142541430
SN - 0002-8703
VL - 256
SP - 2
EP - 12
JO - American heart journal
JF - American heart journal
ER -